DURECT Corporation (Nasdaq: DRRX), a US-based biopharmaceutical company, announced on Tuesday that it has named Timothy M Papp as its new chief financial officer.
In the new role, Papp will direct and manage all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations.
Papp has more than 25 years of corporate finance experience, including 15 years in the Biopharma sector. He has served as managing director of Healthcare Investment Banking at RBC Capital Markets, He has held the position of managing director of Healthcare Investment Banking at Stifel. He has also served in Investment Banking and Mergers & Acquisitions roles at Cowen, Keybanc Capital Markets, and Rodman & Renshaw.
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management